Fresenius Medical Care AG & Co. KGaA
FMS · NYSE
Company research
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) is the world's largest and only fully vertically integrated dialysis company, headquartered in Bad Homburg, Germany, and founded in 1996. Under the leadership of CEO Helen Giza, the company provides comprehensive kidney care services to approximately 343,000 patients through a global network of over 4,000 dialysis clinics spanning more than 50 countries, while also serving the broader population of around 3.9 million patients worldwide who regularly undergo dialysis treatment. As the world's leading provider of dialysis products, Fresenius Medical Care holds over 40% of the global hemodialysis products market share, manufacturing and distributing a broad portfolio including hemodialysis machines, dialyzers, peritoneal dialysis systems, water treatment systems, renal pharmaceuticals, and acute cardiopulmonary and apheresis products. With approximately 108,165 full-time employees and a market capitalization of approximately $13 billion, the company operates through its Care Delivery and Care Enablement segments, generating around €20 billion in annual revenue, with services accounting for roughly three-quarters of sales.
Research reports
Macroaxis · June 27, 2026Fresenius Medical Care Stock Market Outlook
Model-based outlook for Fresenius Medical Care over a three‑month horizon concludes with a Hold recommendation, emphasizing that valuation, momentum, volatility, and sentiment inputs produce balanced but non‑directional signals, modest upside to the 25.49 consensus target price, and low distress risk versus peers.
Sure Dividend · March 15, 2026Fresenius Medical Care AG (FMS) – Sure Analysis Research ReportDividend-focused fundamental analysis updated March 15, 2026 projects approximately 13% annual total returns through 2031 based on 3% EPS growth, a 3.6% dividend yield, and valuation multiple expansion, but maintains a Hold rating because of Fresenius Medical’s uneven historical growth and limited dividend growth in U.S. dollars after German withholding tax.